Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Isoquercetin - Quercis Pharma

Next Previous
Drug Profile

Isoquercetin - Quercis Pharma

Alternative Names: IQC-950AN; Isoquercetin-Quercis Pharma; Isoquercitrin; ISQ950AN; Kinisoquin

Latest Information Update: 28 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Quercis Pharma
  • Developer National Heart, Lung and Blood Institute; Quercis Pharma
  • Class Antianaemics; Antineoplastics; Antithrombotics; Antivirals; Flavonoids
  • Mechanism of Action Blood coagulation factor inhibitors; P selectin inhibitors; Platelet activating factor inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Venous thromboembolism
  • Phase II Amyotrophic lateral sclerosis; Cancer metastases; Sickle cell anaemia; Viral infections
  • Phase I/II Renal cancer; Renal cell carcinoma
  • Research Ovarian cancer
  • No development reported SARS-CoV-2 acute respiratory disease
  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 28 Oct 2025 No recent reports of development identified for research development in SARS-COV-2 acute respiratory disease in USA (PO)
  • 21 Oct 2025 Phase-III clinical trials in Venous thromboembolism (Late-stage disease, Metastatic disease, Prevention, Second-line therapy or greater) in USA (PO) (NCT06861088)
  • 20 Oct 2023 Isoquercetin is still in phase II trials for Amyotrophic lateral sclerosis in the US (Quercis Pharma pipeline, October 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top